Synergistic effect of CGS16949A and 5-fluorouracil on a human breast cancer cell line.

Abstract

The effects of the aromatase inhibitor, CGS16949A, and the fluoropyrimidine, 5-fluorouracil (5-FU), on cell cycle distribution and growth were studied using FACS analysis and MTT assay in the human breast cancer cell line, SK-BR-3. CGS16949A induced an increase in the G0-G1 fraction on SK-BR-3 cells, and the growth inhibition rate of the combination of both (65.7 +/- 3.0%) was significantly higher than 10 nM CGS16949A (37.9 +/- 6.9%) or 100 microg/ml 5-FU (45.6 +/- 4.5%); p < 0.01). Administering 5-FU after preincubation with CGS16949A significantly increased the combined cytotoxic efficacy, suggesting that clinical therapy using this combined therapy may be more efficient.

• Authors: Y Tsunoda, Y Shimizu, A Tsunoda, M Shibusawa, K Kamiya, M Kusano, K Fukuchi
• Journal: European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes (Eur Surg Res) 2001 May-Jun Vol. 33 Issue 3 Pg. 232-6 ISSN: 0014-312X [Print] Switzerland
• PMID: 11490127 (Publication Type: Journal Article)
• Copyright: Copyright 2001 S. Karger AG, Basel

Chemical References

• Antimetabolites, Antineoplastic
• Antineoplastic Agents, Hormonal
• Aromatase
• Fadrozole
• Fluorouracil

Topics

• Antimetabolites, Antineoplastic (pharmacology)
• Antineoplastic Agents, Hormonal (pharmacology)
• Aromatase (metabolism)
• Breast Neoplasms (enzymology, pathology)
• Cell Cycle (drug effects)
• Dose-Response Relationship, Drug
• Drug Synergism
• Fadrozole (pharmacology)
• Female
• Fluorouracil (pharmacology)
• Humans
• Tumor Cells, Cultured (drug effects)